| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-1 Receptor Antagonist Protein; DIRA; IRAP; IL1F3; IL1RA; MVCD4; IL-1RN; IL-1ra; IL-1ra3; ICIL-1RA |
| Entrez GeneID | 3557 |
| WB Predicted band size | Calculated MW: 20 kDa; Observed MW: 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthetic peptide of human IL1RA |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
1. **"Interleukin-1 receptor antagonist: a new member of the interleukin 1 family"** by Arend, W.P. et al.
*摘要：* 该研究首次纯化并鉴定了IL-1受体拮抗蛋白(IL-1RA)，证明其通过竞争性抑制IL-1与受体的结合调控炎症反应，奠定了其在自身免疫疾病中的潜在治疗价值。
2. **"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist"** by Bresnihan, B. et al.
*摘要：* 临床试验证实，重组人IL-1RA(Anakinra)可显著改善类风湿性关节炎患者的症状，验证了IL-1信号通路在该疾病中的关键作用及靶向治疗的可行性。
3. **"Targeting interleukin-1 in autoinflammatory diseases"** by Dinarello, C.A.
*摘要：* 综述IL-1家族生物学功能，重点讨论IL-1RA作为治疗剂在痛风、周期性发热综合征等疾病中的应用机制及临床研究进展。
4. **"IL-1 receptor antagonist protein (IRAP) in inflammation and cancer"** by Gabay, C. et al.
*摘要：* 探讨IL-1RA在炎症相关癌症中的双重角色，包括抑制肿瘤生长与潜在促转移效应，强调其抗体在治疗开发中的挑战与前景。
---
注：以上文献名为示例，实际引用需核对具体来源及年份。建议通过PubMed或Web of Science以关键词“IL-1RA antibody”或“IL-1 receptor antagonist”检索最新或高引论文。
The IL-1 Receptor Antagonist Protein (IL-1RA) is a naturally occurring cytokine inhibitor that competitively binds to the interleukin-1 receptor (IL-1R), blocking the pro-inflammatory effects of IL-1α and IL-1β. As a critical regulator of innate immunity, IL-1RA modulates excessive inflammatory responses implicated in autoimmune diseases, sepsis, and osteoarthritis. Antibodies targeting IL-1RA are essential tools for detecting and quantifying this protein in research and clinical settings.
These antibodies are typically developed using recombinant IL-1RA or peptide immunogens, enabling specificity for human, mouse, or other species' variants. They facilitate applications such as Western blotting, ELISA, immunohistochemistry, and flow cytometry to study IL-1RA expression patterns in tissues, immune cells, or biological fluids. In disease research, IL-1RA antibodies help investigate its role as a biomarker in rheumatoid arthritis, inflammatory bowel disease, and cardiovascular conditions. They also support therapeutic monitoring of recombinant IL-1RA drugs like anakinra, a clinically approved treatment for rheumatoid arthritis.
Validation often involves knockout cell lines or neutralizing activity assays to confirm target specificity. Cross-reactivity with structurally related cytokines must be ruled out during development. As IL-1RA exists in multiple isoforms (intracellular and secretory), antibody selection depends on the intended experimental focus. Recent studies also utilize IL-1RA antibodies to explore its paradoxical dual roles in both suppressing inflammation and promoting tissue repair mechanisms.
×
